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Abstract
Objective—Little is known about survival after a diagnosis of a second or higher order
(multiple) primary melanoma. We aimed to determine whether survival after diagnosis was better
in patients with multiple primary melanomas (MPM) than with single primary melanomas (SPM),
as suggested in a recent study.
Design—Survival analysis with median follow-up of 7.6 years (range 0.4-10.6).
Setting—The Genes, Environment and Melanoma (GEM) study enrolled incident cases of
melanoma notified to population-based cancer registries in Australia, Canada, Italy and the USA.
MPM were ascertained over a longer period than SPM.
Participants—2372 patients with SPM and 1206 with MPM.
Main outcome measures—Melanoma-specific fatality hazard ratios (HR) and confidence
intervals (CI) associated with clinical and pathologic characteristics of SPM, MPM and both
together in Cox regression models.
Results—Thickness was the main determinant of fatality (HR for >4mm=7.68, 95% CI 4.46 to
13.23); other independent predictors were ulceration, mitoses and scalp location. After adjustment
for these other predictors, there was little difference in fatality between MPM and SPM (HR for
MPM relative to SPM=1.24, 95% CI 0.91 to 1.69; P = .18). Thicker SPM, however, had higher
fatality (HR for >4mm=13.56, 95% CI 6.47-28.40) than thicker MPM (HR for >4mm=2.93, 95%
CI 1.17-7.30).
Conclusion—While overall fatalities from SPM and MPM were similar, relative fatality for
thick SPM was greater than for thick MPM. This finding may offer support for a difference in
outcome between patients with SPM and MPM that is worth further exploration.
Keywords
GEM; MPM; SPM; pathology characteristics; fatality; survival
INTRODUCTION
Subsequent melanomas in patients with multiple primary melanomas are well known to be
thinner, on average, than prior melanomas and might therefore have a better outcome.1-3
Whether survival is better or worse for patients diagnosed with multiple primary melanomas
(MPM) than a single primary melanoma (SPM) is important for prognosis. Results from
earlier studies examining survival of SPM and MPM offer little consistent information; they
had few patients, limited analysis to selected stage categories, or presented crude survival
estimates only.4-7 A recent assessment based on 4952 SPM and 298 MPM melanoma clinic
patients with stage 1 or 2 disease, however, suggested that patients with multiple primary
melanomas survived longer than those with a single primary melanoma after taking account
of other prognostic factors.8 Among possible mechanisms for an apparent survival benefit,
the authors discuss whether multiple melanomas may provoke a stronger host immune
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response,8 which might also explain better survival for MPM than SPM after diagnosis of
metastatic disease.9 Additionally, the possibility that both initial and subsequent melanomas
are thinner in MPM than SPM has given rise to speculation that MPM may be biologically
different from SPM.2,10
No study has yet explored survival in a population-based sample that included patients with
single and patients with multiple primary melanomas of any stage. Our analysis was
undertaken to determine whether survival after diagnosis with MPM was better than after
diagnosis with SPM in the large, population-based Genes, Environment and Melanoma
(GEM) study. Specifically, we analyze detailed pathologic features of the melanomas to
identify their contribution to overall survival and to survival in MPM and SPM separately,
and to explore whether differences in these contributions suggest biological differences
between MPM and SPM that affect outcome.
METHODS
GEM enrolled incident cases of primary melanoma registered in population-based cancer
registries in Australia, Canada, Italy and the USA (see1,11). Briefly, SPM were diagnosed
with a first invasive primary melanoma in 2000 and MPM with a second or higher order
invasive or in situ melanoma in 1998-2003 (referred to as the recent MPM); all patients
provided written informed consent. Institutional Review Boards at the Memorial Sloan–
Kettering Cancer Center, New York, and each contributing centre approved the study
protocol.
A total of 2372 SPM and 1206 MPM were eligible for the survival analyses. Breslow
thickness and anatomic site were abstracted from community pathologists’ and expert
review reports1 while ulceration and mitoses were available only from the latter; more SPM
(87%) than recent (79%) or prior MPM (65%) had slides available for review. Information
on nodal metastases was unavailable. Among other items, patients were asked at interview
for education, used as a surrogate for socioeconomic status in these analyses, and history of
melanoma in first degree relatives.
We analyzed melanoma-specific survival in SPM and MPM patients by tumor pathology
characteristics. For MPM patients we included in the analysis the pathology characteristics
of the melanoma considered most likely to cause death, which was selected using an
algorithm based on stage at and time between diagnosis of the melanomas (see, for
example9). Characteristics of the recent MPM were used in statistical models when
melanomas were diagnosed more than 5 years apart, except when the most recent MPM was
in situ, since the prior melanoma is less likely to be responsible for clinical outcome in
patients who survive 5+ years after diagnosis. For melanomas less than 5 years apart, the
characteristics of the MPM with the highest known AJCC tumor stage were used. When
both melanomas were <=1mm thick, the presence of mitoses was considered to indicate the
higher stage. Patient follow-up to ascertain deaths finished at the end of 2007 in most
centres and 2008 in British Columbia and Torino.
Age at diagnosis of SPM or the selected MPM was designated the ‘age at diagnosis’ for
analysis. Cumulative percentage incidence and mortality was plotted by 5 year age groups to
investigate the apparent rarity of deaths at younger ages in MPM than SPM. For survival
analyses, melanoma-specific survival time was accumulated from the diagnosis date of the
SPM or the most recent MPM to melanoma death; all other cases were censored at the end
of follow-up or at death from other causes. Kaplan-Meier methods were used to estimate
survival proportions in SPM and MPM separately and test for differences using the log rank
test. We used Kaplan-Meier methods also to estimate survival proportions in SPM and
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MPM separately and to construct survival curves for all SPM and MPM by thickness
(≤2mm, >2mm) and age (<70, 70+ years) and tested the associations between survival and
these factors using the log rank test; all P values were <0.05 for difference between the two.
Hazard ratios (HR) and 95% confidence intervals (CI) associated with SPM or MPM status,
Breslow thickness, Clark level, presence of vertical growth, ulceration, mitoses and site
were estimated in Cox proportional hazard regression models for all SPM and MPM
including, as covariates, age as a continuous variable, sex and study center. To display the
influence of age we present estimates for age grouped in decades. Cases with missing values
were included in these models using missing values categories for relevant variables. We
constructed a variable for AJCC tumor sub-stages using thickness and ulceration or mitoses
to define stage 1 and thickness and ulceration for stages 2, 3 and 4. Information on
metastases was unavailable.
We also estimated HRs associated with SPM or MPM status, thickness, ulceration, mitoses
and site in multivariable models for all SPM and MPM, adjusted for age, sex, center, and
including education and family history as potential confounders; the models excluded
patients with missing information except where family history was missing, for which a
missing value category was used to retain 6% of patients lacking this information. To assist
in evaluating whether there was a difference in effect estimates for each of thickness,
ulceration, mitoses and site by SPM or MPM status, we estimated P values for interaction,
using the Wald test to compare the multivariable model with main effects only with a model
with main effects and the cross-product term.
The associations of pathology variables with survival were evaluated separately for men and
women and separately also for SPM and MPM, and we examined the influence of time
between MPM using three time intervals (<3 months, 3 months to 5 years, >5 years). All P
values were two sided and P <.05 was considered statistically significant. Tests based on
Schoenfeld residuals and graphical methods using Kaplan-Meier curves in STATA/SE 8.2
showed little evidence that the proportional hazards assumption was violated. SAS software
version 9.1 was used for all other statistical analyses.
RESULTS
A total of 563 deaths occurred including 255 deaths from melanoma, 152 SPM and 103
MPM deaths. The median follow-up times were 8 years from diagnosis of an SPM and 6.6
years from diagnosis of the most recent MPM (7.6 years for all patients, range 0.4-10.6
years). Kaplan Meier survival estimates were more favorable at 7 years for SPM than MPM
(93.8% vs 90.3%; P=.001) although they were identical at 3 years (97.2%) and very similar
at 5 years (95.1% SPM, 94.1% MPM). Compared with SPM, dates of diagnosis of the most
recent MPM and death from melanoma were shifted towards older ages; there were no
deaths before age 50 in MPM (Figure 1). MPM patients were older (mean age 62.9 years,
range 7 to 95) than SPM patients (mean age 54.8 years, range 9 to 97) and the mean age at
death was 65 years (range 23–93) in SPM and 73 (55–90) in MPM. MPM were more likely
to be in men (66% M, 34% F) than SPM (52% M, 48% F) and men had more >2mm MPM
than women (73% M, 27% F).
The most recent MPM was generally thinner than the previous one1 although >4mm lesions
were as likely in MPM (5%) as SPM (5%; P=.7). The average tumor size in men was similar
for SPM and MPM (1.45mm and 1.43mm; P=.11) but women had thicker SPM than MPM
(1.20mm SPM, 1.11mm MPM; P <.001).
As a preliminary to comparing survival in SPM and MPM, we analyzed effects of other
clinical and pathologic factors on survival in models including age, sex, and study center.
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Deeper invasion, whether assessed by Breslow thickness, Clark level or presence of vertical
growth increased risk of melanoma death strongly (eTable 1). Unadjusted 5 year survivals
for >2mm melanomas were 72% at 70+ years and 84% at <70 years and similar for men and
women although deaths were rare in women aged <70 (Figure 2).
We constructed a multivariable model to include all variables with P<.1 in single variable
analyses, adjusted for age, sex, center, and including family history and education; the
multivariable model included 2770 patients with complete information. Increasing thickness
(HR for >4mm=7.68, 95% CI 4.46-13.23), ulceration, presence of mitoses and scalp location
(HRs up to 2.25) were each independently associated with increased melanoma fatality (P<.
05 in each case), and age <40 years with reduced risk (HR=0.44, 95% CI 0.23-0.84) (Table
1). There was statistical evidence that the relationship between thickness and fatality was
different for SPM and MPM (P for interaction .004), but not between ulceration or mitoses
and fatality. Although fatality was much less in women when adjusted for age and center
only (HR=0.56, 95% CI 0.43-0.75, relative to men), there was no evidence of a difference in
fatality in the fully adjusted model (HR=0.86, 95% CI 0.62-1.20). In separate analyses for
men and women, the patterns of increasing risk with increasing thickness and an increased
HR with ulceration were also present, while mitoses increased fatality in men (by 80%) but
not in women (data not shown).
The HRs for AJCC tumor “b” substages were around 1.5-2 fold higher than for “a”
substages for each thickness category, relative to melanomas ≤1mm with no ulceration or
mitoses (Table 2). The patterns of risk by AJCC tumor stage were very similar in separate
analyses in men and women as in both sexes combined (data not shown). Fewer women than
men had ulcerated MPM (5% of all melanomas in F, 9.3% in M); 5 year survival
proportions by ulceration in both sexes were 77% with ulceration and 96% in its absence.
When we examined SPM and MPM in separate multivariable models, fatality of SPM
increased with increasing thickness to HR=10.45, 95% CI 5.21-20.97 for 2.01-4mm and
HR=13.56, 95% CI6.47-28.4 for >4mm. For MPM, however, HRs for all categories of
thickness were around 2.6-2.9 and had no evidence of a trend (eTable 2). Ulceration and
mitoses had HRs between 1.5 and 2.0 for each of SPM and MPM but the estimates were
statistically significant only for ulceration in SPM and mitoses in MPM. Melanoma on the
scalp increased risk 2.5-fold and age <60 at diagnosis reduced risk substantially for each of
SPM and MPM.
There was no evidence of variation in fatality of MPM by time interval between the
melanomas (results not shown).
DISCUSSION
Contrary to Doubrovsky and Menzies’ finding of more favorable survival for MPM than
SPM after controlling for prognostic factors,8 we found the fatality after a diagnosis of
MPM to be overall a little higher than that after a diagnosis of SPM, but not significantly so.
Our study though was population-based and included melanomas of any stage, theirs
included stages 1 and 2 only. Thickness was the most important determinant of survival in
GEM patients with SPM and with MPM, as it is for melanoma generally.12,13 Ulceration
and the presence of mitoses among pathology characteristics and location on the scalp were
also independently associated with increased fatality of both as was increasing age.
Thickness is a well-established prognostic factor for survival in primary melanomas, with
relative survival proportions of 50% for 4+mm but nearly 100% for <0.75mm melanomas at
5 and 10 years after diagnosis.12 Similarly in GEM, survival was much poorer for >4mm
than ≤1 mm thickness and additionally, we observed a relative risk of death following a
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>4mm melanoma that was 4.6 times higher for SPM than MPM despite similar proportions
of >4mm lesions in SPM and MPM patients. Doubrovsky and Menzies reported a significant
effect of thickness on melanoma death in their study but did not report on SPM and MPM
separately.8 Another study investigated whether a less aggressive biology in MPM,
represented by mitotic rate, was a possible explanation for the generally thinner lesions in
MPM and SPM but concluded that it was not and that other factors such as increased
surveillance or genetic constitution probably contribute.10
We evaluated the prognostic significance for SPM and MPM of a number of other
pathologic factors known to be associated with a poor outcome in primary melanomas.
Risks of death were higher for a given thickness in the presence of ulceration than in its
absence, in consistency with the increased severity ulceration confers at each stage in AJCC
melanoma tumor staging definitions.14 In GEM, ulceration was as likely in SPM and MPM
(7% and 8% respectively), as elsewhere,15 but we found little evidence of a difference
between SPM and MPM in its effect on survival. Similarly, mitotic rate is an accurate and
independent predictor of survival,14,16-20 but its effect was also little different between SPM
and MPM. That similar mitotic rates have been observed for SPM and MPM suggests little
difference in underlying biologic aggressiveness between SPM and MPM lesions.10
We also examined other clinical factors. A poorer outcome for scalp than facial sites,
usually in older men,12,21,22 has not been investigated fully in previous relevant MPM
studies4,8 but is considered to be due to tumor factors.12,20-22 Scalp melanomas in GEM
were similarly fatal in SPM and MPM and apparently had a higher fatality in women than
men, consistent with possible late stage diagnosis in women (35% of scalp SPM in women
were >2mm).
Survival was more favorable in younger people in our study and worsened with increasing
age. Age 70+ years is suggested to worsen melanoma prognosis,12,16,17,23 an outcome that is
independent of thicker lesions in older patients,24 probably because age is a surrogate for a
declining host defense system.14,17
The poorer survival in men than women reported for primary melanomas12 is suggested to
be due to late stage diagnosis in men.23,25 We found limited evidence, however, for poorer
outcomes in men in our data, mainly that survival was somewhat poorer for thicker
melanomas in men (see Figure 2), and they had more melanomas with ulceration. The
relatively small number at age 70+ of women with MPM (24% of MPM in women) is not
unexpected, given that melanoma incidence at older ages is lower in women than men
(http://seer.cancer.gov/csr/1975_2007/).
Major strengths of our study are the population-based ascertainment, the extensive
clinicopathologic information on prognostic variables and the expert pathologic review for
many slides.1 Information on ulceration and mitoses was missing more often for MPM than
SPM (32% missing vs 18%) because pre-2000 tumors, many of which were prior MPM,
were more often unavailable for expert review (45% post 1999 vs 19% pre-2000; p<.001). It
may be a weakness also that GEM did not identify SPM patients who had another melanoma
diagnosed between the close of initial study enrolment and the end of followup. The
resulting misclassification of SPMs as MPMs would have tended towards reducing any
observed difference between them in overall fatality and in fatality associated with >4mm
lesions. The study also lacked information about nodal or metastatic disease at diagnosis and
time to relapse or recurrence. The different health care systems in place in GEM centers in
the USA, Canada, Italy and Australia could have been a source of differences in access to
diagnosis or care for patients. We sought to address this issue by including center as a
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covariate in all analyses and additionally, education as a surrogate for socioeconomic status
in all multivariable models.
In summary, we found no strong evidence of a difference in survival between SPM and
MPM, despite the evidence of others8 and suggestions that MPM may have a less aggressive
biology than SPM.2,8,10 We report for the first time, however, a greater increase in risk of
death with increasing tumor thickness for SPM than MPM: this was the main feature that
indicated a possible difference between outcome in patients with single or multiple
melanomas.
Doubrovsky and Menzies reported that an increasing number of melanomas influenced
survival favorably.8 They suggested that the effects of immunological surveillance against
melanomas may be substantial in MPM patients.8 The results of our study suggest that
preference be given to further investigation of this hypothesis over effects simply of closer
surveillance and earlier diagnosis as a potential explanation for generally thinner lesions,
and an apparently better outcome for the thickest lesions, in MPM than SPM patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Cumulative percentage distributions of cases by age at diagnosis (SPM) or at diagnosis of
the selected lesion (MPM) and of melanoma deaths by age at death in 2372 SPM (152
melanoma deaths) and 1206 MPM (103 deaths) GEM patients.
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Figure 2.
Kaplan-Meier survival curves showing melanoma-specific survival for >2mm melanomas
diagnosed at <70 or 70+ years of age in (A) men and women combined, (B) men, (C)
women.
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Table 1
Hazard ratios for melanoma death associated with status as SPM or MPM, and age, sex and pathology
characteristics.
Characteristic Censored N=2561 Dead N=209 HR (95% CI)a P
Status
    SPM 1788 126 1.0
    MPM 773 83 1.24 (0.91-1.69) .18
Age at diagnosis (years)
    <40 383 12 0.44 (0.23-0.84)
    40-49 424 20 0.65 (0.38-1.11)
    50-59 554 35 0.78 (0.50-1.20)
    60-69 511 57 0.95 (0.65-1.38)
    70-79 532 62 1.0
    80+ 157 23 0.97 (0.59-1.59) .15
Sex
    Male 1411 149 1.0
    Female 1150 60 0.86 (0.62-1.20) .38
Site
    Trunk 1140 90 1.0
    Scalp 60 21 2.25 (1.37-3.71)
    Other head and neckb 340 39 1.10 (0.74-1.63)
    Arms 466 31 0.74 (0.49-1.12)
    Legs 555 28 0.65 (0.41-1.02) <.001
Thickness (mm)
    0.01-1.00 1724 40 1.0
    1.01-2.00 515 63 3.42 (2.18-5.37)
    2.01-4.00 230 68 5.65 (3.44-9.28)
    >4.00 92 38 7.68 (4.46-13.23) <.001
Ulceration
    Absent 2366 142 1.0
    Present 195 67 1.70 (1.22-2.37) .002
Mitosis
    Absent 1510 43 1.0
    Present 1051 166 1.64 (1.08-2.51) .02
Abbreviations: SPM, single primary melanoma; MPM, multiple primary melanoma; HR, hazard ratio; CI, confidence interval.
Censored/melanoma deaths by center in 2770 patients: New South Wales (Australia) 1079/111; Tasmania (Australia) 105/11; British Columbia
(Canada) 132/8; Ontario (Canada) 420/31; Turin (Piemonte, Italy) 62/8; California (Orange County and San Diego) 141/3; Michigan (USA)
263/21; New Jersey (USA) 104/8; and North Carolina (USA) 255/8.
aAdjusted for age (continuous), sex, center, family history, education and all other variables in the table; HRs for age were estimated in a model of
age grouped by decade. Excludes patients with missing data, most commonly due to lack of information on ulceration or mitoses in melanomas for
which pathology could not be reviewed (18% SPM, 32% MPM). A missing value indicator was used for family history. Time of origin for MPM is
date of diagnosis and pathology variables for MPM are those of the selected MPM.
bOther head and neck includes ears, face, unspecified face, neck.
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Table 2
Hazard ratios for melanoma death by American Joint Committee on Cancer (AJCC) melanoma tumor stage.
AJCC tumor stage Censored N=3323 Dead N=255 HR (95% CI)a
T1a ≤1.0mm a. no ulceration or mitoses 1346 25 1.0
T1b b. ulceration or mitoses 390 15 2.09 (1.10-3.96)
T2a 1.01-2.0mm a. without ulceration 460 52 5.45 (3.37-8.80)
T2b b. with ulceration 58 13 9.48 (4.82-18.64)
T3a 2.01-4.0mm a. without ulceration 152 37 10.87 (6.53-18.10)
T3b b. with ulceration 81 31 15.30 (8.97-26.10)
T4a >4.0mm a. without ulceration 53 17 12.96 (6.96-24.13)
T4b b. with ulceration 39 23 23.00 (12.85-41.14)
Unknown 744 42 3.19 (1.89-5.41)
P<.001
Abbreviations: SPM, single primary melanoma; MPM, multiple primary melanoma; HR, hazard ratio; CI, confidence interval, AJCC American
Joint Committee on Cancer.
aAdjusted for age, sex, center, melanoma status (SPM or MPM), family history, education and site (5 level); time of origin for MPM is date of
diagnosis and pathology variables are those of the selected MPM. Patients with missing data are included in the ‘unknown’ category’, mostly for
ulceration or mitoses in melanomas for which pathology could not be reviewed (18% SPM, 32% MPM). A missing value indicator was used for
family history.
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